Global Cell and Gene Therapy Market 2022

March 2022 | 18 pages | ID: G13EE67F55E4EN
StrategyHelix Inc

Abstracts

Cell and gene therapy, represent overlapping fields of biomedical research with similar therapeutic goals, which target DNA or RNA inside or outside the body. Both therapies aim to treat, prevent, or potentially cure diseases, and both approaches have the potential to alleviate the underlying cause of genetic diseases and acquired diseases. The global cell and gene therapy market is set to increase by US$ 14,747 million from 2022 to 2028, representing a compound annual growth rate (CAGR) of 29.1% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for cell and gene therapy. The global cell and gene therapy market is segmented on the basis of therapy type, product, application, and region. On the basis of therapy type, the global cell and gene therapy market has been segmented into gene therapy, cell therapy, others. By product, the global cell and gene therapy market has been segmented into Zolgensma, Yescarta, Kymriah, Zynteglo, Maci, Tecartus, others. Based on application, the global cell and gene therapy market is categorized into rare diseases, oncology, hematology, ophthalmology, neurology, others. In terms of geography, the global cell and gene therapy market has been segmented into North America, Asia Pacific, Europe, Middle East and Africa, Latin America.

The global cell and gene therapy market is highly competitive. As of 2021, the major players in the global cell and gene therapy market were Amgen Inc., bluebird bio Inc., Dendreon Pharmaceuticals LLC, Gilead Sciences Inc., Novartis International AG, Orchard Therapeutics plc, Shenzhen SiBiono GeneTech Co. Ltd., Spark Therapeutics Inc., Vericel Corporation.

Report Scope
Therapy type: gene therapy, cell therapy, others
Product: Zolgensma, Yescarta, Kymriah, Zynteglo, Maci, Tecartus, others
Application: rare diseases, oncology, hematology, ophthalmology, neurology, others
Region: North America, Asia Pacific, Europe, Middle East and Africa, Latin America
Years considered: this report covers the period 2018 to 2028

Key Benefits for Stakeholders
Get a comprehensive picture of the global cell and gene therapy market
Pinpoint growth sectors and trends for investment

Contents

PART 1. INTRODUCTION

Scope of the study
Study period
Geographical scope
Research methodology

PART 2. CELL AND GENE THERAPY MARKET OVERVIEW

PART 3. MARKET BREAKDOWN BY THERAPY TYPE

Gene therapy
Cell therapy
Others

PART 4. MARKET BREAKDOWN BY PRODUCT

Zolgensma
Yescarta
Kymriah
Zynteglo
Maci
Tecartus
Others

PART 5. MARKET BREAKDOWN BY APPLICATION

Rare diseases
Oncology
Hematology
Ophthalmology
Neurology
Others

PART 6. MARKET BREAKDOWN BY REGION

North America
Asia Pacific
Europe
Middle East and Africa
Latin America

PART 7. KEY COMPANIES

Amgen Inc.
bluebird bio, Inc.
Dendreon Pharmaceuticals LLC
Gilead Sciences, Inc.
Novartis International AG
Orchard Therapeutics plc
Shenzhen SiBiono GeneTech Co., Ltd.
Spark Therapeutics, Inc.
Vericel Corporation
About StrategyHelix
Disclaimer